Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities

Molecular & Cellular Proteomics(2021)10.1016/j.mcpro.2021.100182Source: DataRank Database

Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities is a research paper published in Molecular & Cellular Proteomics (2021). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

pxd doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.61)OA: goldTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Prathyusha Konda ORCID,J. Patrick Murphy ORCID,Joao A. Paulo ORCID,Steven P. Gygi ORCID,Shashi Gujar ORCID

Live enrichment

PubMed:34922008 PMC:PMC8864471 OpenAlex:https://openalex.org/W4200152005

National Institute of General Medical Sciences

Grant: R01 GM132129

National Institute of General Medical Sciences

Grant: GM67945

NIGMS NIH HHS

Grant: R01 GM067945

Canadian Institutes of Health Research

National Institutes of Health

Dalhousie Medical Research Foundation

FWCI

0.61

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.mcponline.org/article/S1535947621001547/pdf

publisherhttp://www.mcponline.org/article/S1535947621001547/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535947621001547?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535947621001547?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.mcpro.2021.100182

Fields of Study

Virus-based gene therapy researchCAR-T cell therapy researchImmunotherapy and Immune ResponsesAnimalsCD8-Positive T-LymphocytesCell Line, TumorImmune Checkpoint InhibitorsImmunotherapyMajor Histocompatibility ComplexNeoplasmsOncolytic Viruses

MeSH Terms

Immune Checkpoint InhibitorsAnimalsImmunotherapyMajor Histocompatibility ComplexNeoplasmsCD8-Positive T-LymphocytesCell Line, TumorOncolytic Viruses

Keywords

Oncolytic virusCD8MHC class IImmunotherapyCytotoxic T cellMajor histocompatibility complexImmune checkpointT cellCancer researchEpitopeCancer immunotherapyImmune systemImmunologyBiologyCancerAntigenBiochemistryAntitumor immunityImmune Checkpoint BlockadeMhc-i PeptidomeOncolytic Reovirus

Sustainable Development Goals

SDG 0: Good health and well-being

Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities

FAIR Checklist

Authors (6)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)